Characteristics of Marketed Nanopharmaceutics
| dc.authorscopusid | 26436187600 | |
| dc.authorscopusid | 57212018375 | |
| dc.contributor.author | Şalva E. | |
| dc.contributor.author | Tonbul H. | |
| dc.date.accessioned | 2024-08-04T20:04:02Z | |
| dc.date.available | 2024-08-04T20:04:02Z | |
| dc.date.issued | 2021 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | This chapter discusses different types of nanopharmaceuticals and their current marketed status. With the development of nanotechnology and nanoscience in every branch of science in recent years and their merging with medicine gave rise to the nanopharmaceutical concept and colloidal dispersion systems re-emerged as nanopharmaceuticals. Nanopharmaceutics are new therapeutics that are developing rapidly with advances in nanotechnology and pharmaceutical sciences. Clinical trials are being conducted on many nanopharmaceuticals, and some of them are already on the market. Lipid-based and liposomal nanopharmaceutics are preferred as carrier systems for many conventional drugs, especially for drugs that are poorly soluble and highly toxic. Crystalline nanoparticles are important in drug delivery because of their properties such as their nanosize, 100% drug component composition, a large surface area for dissolution, and the ability to provide an extended release profile for poorly soluble drugs. The majority of the nanopharmaceutical market revenue comes from therapeutics, including drugs, devices, and drug delivery systems. © 2022 Jenny Stanford Publishing Pte. Ltd. | en_US |
| dc.identifier.doi | 10.1201/9781003164739-26 | |
| dc.identifier.endpage | 724 | en_US |
| dc.identifier.isbn | 9781000375268 | |
| dc.identifier.isbn | 9789814877756 | |
| dc.identifier.scopus | 2-s2.0-85128019110 | en_US |
| dc.identifier.scopusquality | N/A | en_US |
| dc.identifier.startpage | 705 | en_US |
| dc.identifier.uri | https://doi.org/10.1201/9781003164739-26 | |
| dc.identifier.uri | https://hdl.handle.net/11616/92313 | |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor and Francis | en_US |
| dc.relation.ispartof | Drug Delivery with Targeted Nanoparticles: In Vitro and in Vivo Evaluation Methods | en_US |
| dc.relation.publicationcategory | Kitap Bölümü - Uluslararası | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | [No Keyword] | en_US |
| dc.title | Characteristics of Marketed Nanopharmaceutics | en_US |
| dc.type | Book Chapter | en_US |
